

GLP-1 Receptor Agonist Market Report

Diabetes and Obesity Treatment Landscape

GLP-1 receptor agonists have revolutionized the treatment of type 2 diabetes and obesity, with unprecedented demand driving supply constraints globally.

Market Leaders:

- Semaglutide (Ozempic/Wegovy): USD 21B revenue 2023
- Tirzepatide (Mounjaro/Zepbound): Fastest launch ever
- Liraglutide (Victoza/Saxenda): Established market leader
- Dulaglutide (Trulicity): Strong US presence

Clinical Development:

- SURPASS trials: Tirzepatide superior A1C reduction
- SELECT trial: CV risk reduction with semaglutide
- STEP trials: Up to 22% body weight loss

Market Forecast:

GLP-1 market expected to exceed USD 100B by 2030 driven by obesity indication expansion.